{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:50:31Z","timestamp":1794963031792,"version":"4.9.1"},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.2169\/internalmedicine.6070-25","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T22:08:17Z","timestamp":1755727697000},"page":"1056-1060","source":"Crossref","is-referenced-by-count":4,"title":["Amyloid Clearance and Transient CSF A\u03b240 Reduction in a Case of ARIA-E\/H Following Lecanemab Treatment"],"prefix":"10.2169","volume":"65","author":[{"given":"Yuki","family":"Naeshiro","sequence":"first","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Kyoto Prefectural University of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukiko","family":"Kitani-Morii","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Kyoto Prefectural University of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kasai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Kyoto Prefectural University of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eijirou","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Kyoto Prefectural University of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Kyoto Prefectural University of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Kyoto Prefectural University of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer&apos;s Disease. N Engl J Med 388: 9-21, 2023.","DOI":"10.1056\/NEJMoa2212948"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer&apos;s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11: 241-249, 2012.","DOI":"10.1016\/S1474-4422(12)70015-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. De Kort AM, Kuiperij HB, Marques TM, et al. Decreased cerebrospinal fluid amyloid \u03b2 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy. Ann Neurol 93: 1173-1186, 2023.","DOI":"10.1002\/ana.26610"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Carmona-Iragui M, Fern\u00e1ndez-Arcos A, Alcolea D, et al. Cerebrospinal fluid anti-amyloid-\u03b2 autoantibodies and amyloid PET in cerebral amyloid angiopathy-related inflammation. J Alzheimers Dis 50: 1-7, 2016.","DOI":"10.3233\/JAD-150614"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Leit\u00e3o MJ, Silva-Sp\u00ednola A, Santana I, et al. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer&apos;s disease. Alzheimers Res Ther 11: 91, 2019.","DOI":"10.1186\/s13195-019-0550-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10: 362-377, 2023.","DOI":"10.14283\/jpad.2023.30"},{"key":"7","doi-asserted-by":"crossref","first-page":"e13231","DOI":"10.1111\/psyg.13231","volume":"25","author":"A Yamazaki","year":"2025","unstructured":"7. Yamazaki A, Sekine T, Takahashi S, et al. A case of severe ARIA with multiple infarctions and extensive microbleeds following lecanemab administration. Psychogeriatrics 25: e13231, 2025.","journal-title":"Psychogeriatrics","ISSN":"https:\/\/id.crossref.org\/issn\/1346-3500","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 16: 30-42, 2020.","DOI":"10.1038\/s41582-019-0281-2"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Sakai K, Hayashi S, Sanpei K, Yamada M, Takahashi H. Multiple cerebral infarcts with a few vasculitic lesions in the chronic stage of cerebral amyloid angiopathy-related inflammation. Neuropathology 32: 551-556, 2012.","DOI":"10.1111\/j.1440-1789.2011.01283.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kim BH, Kim S, Nam Y, Park YH, Shin SM, Moon M. Second-generation anti-amyloid monoclonal antibodies for Alzheimer&apos;s disease: current landscape and future perspectives. Transl Neurodegener 14: 6, 2025.","DOI":"10.1186\/s40035-025-00465-w"},{"key":"11","unstructured":"11. Institute for Clinical anc Economic Review, Lecanemab for Early Alzheimer&apos;s Disease. Final Evidence Report [Internet]. [cited 2023 Apr 17]. Available from: https:\/\/icerorg\/wp-content\/uploads\/2023\/04\/ICER_Alzheimers-Disease_Final-Report_For-Publication_04172023pdf?utm_source=chatgptcom"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zetterberg H, Pedersen M, Lind K, et al. Intra-individual stability of CSF biomarkers for Alzheimer&apos;s disease over two years. J Alzheimers Dis 12: 255-260, 2007.","DOI":"10.3233\/JAD-2007-12307"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ordu\u00f1a Dolado A, Stomrud E, Ashton NJ, et al. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer&apos; disease biomarkers. Alzheimers Res Ther 16: 132, 2024.","DOI":"10.1186\/s13195-024-01503-x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/7\/65_6070-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:55:28Z","timestamp":1775274928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/7\/65_6070-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6070-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"6070-25"}}